Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10.09.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 23.07.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19.07.19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19.07.19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19.06.20 |
William McVicar
CHM | Chairman | 66 | 19.07.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Tess Burleson
BRD | Director/Board Member | 57 | 19.07.19 |
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 4 776 433 | 4 486 213 ( 93,92 %) | 0 | 93,92 % |
Unternehmenskontakt
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+1.67% | 42.59 Mrd. | |
+8.55% | 40.65 Mrd. | |
+49.22% | 40.57 Mrd. | |
-12.36% | 26.77 Mrd. | |
+9.04% | 24.81 Mrd. | |
-24.72% | 18.17 Mrd. | |
+29.25% | 12.05 Mrd. | |
-3.02% | 11.7 Mrd. | |
+6.55% | 11.1 Mrd. |